|
|
|
|
|||||
|
|
|
Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term.
On November 18, JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 while maintaining an Overweight rating after meetings with management. JPMorgan said the discussions reinforced its positive view on the company. The analyst noted that Lilly’s agreement with the Trump Administration to expand access to obesity medicines is a net positive.
Over the past five years, Eli Lilly and Company (NYSE:LLY) has seen major success with its weight loss drugs. The company holds a leading position in the new class of GLP-1 inhibitor drugs, which is significant given the prevalence of obesity and related health risks.
In Q3 2025, revenue rose 54% to $17.60 billion, driven by volume growth from Mounjaro and Zepbound. Reported EPS increased by $5.14 to $6.21, while non-GAAP EPS rose by $5.84 to $7.02. Pipeline progress included positive results in four Phase 3 trials of orforglipron for type 2 diabetes and obesity, with plans to submit for global regulatory approval for obesity treatment by year-end.
Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that discovers, develops, manufactures, and markets medicines addressing medical needs in areas including diabetes, oncology, immunology, neurodegeneration, and pain.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best Long Term Stocks to Buy According to Reddit and 13 Best Canadian Dividend Stocks to Buy and Hold for the Long Term.
Disclosure: None.
| 16 min | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 |
Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial
LLY
The Wall Street Journal
|
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-25 | |
| Nov-24 |
Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps
LLY
Investor's Business Daily
|
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite